Akèy › Kansè vesikil bilyè
Etid klinik pou Kansè vesikil bilyè ap rekrite nan Etazini
14 etid pou Kansè vesikil bilyè ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY4 etid
- Cleveland, OH4 etid
- Nashville, TN4 etid
- Baldwin Park, CA4 etid
- Oklahoma City, OK3 etid
- Omaha, NE3 etid
- Seattle, WA3 etid
- Portland, OR3 etid
- Boston, MA3 etid
- Detroit, MI3 etid
- Philadelphia, PA3 etid
- Pittsburgh, PA3 etid
- Dallas, TX3 etid
- Los Angeles, CA3 etid
- Houston, TX3 etid
- Birmingham, AL3 etid
- Louisville, KY3 etid
Pa eta
- Alabama3 etid
- Colorado4 etid
- Connecticut3 etid
- Florid8 etid
- Illinois4 etid
- Kalifòni9 etid
- Kentucky3 etid
- Massachusetts4 etid
- Michigan4 etid
- Minnesota3 etid
- Nebraska3 etid
- New York5 etid
- North Carolina4 etid
- Ohio7 etid
- Oklahoma3 etid
- Oregon3 etid
- Pennsylvania4 etid
- Tennessee4 etid
- Texas5 etid
- Washington3 etid
- Wisconsin3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07265674A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07221253DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Ap rekriteFaz 2
Laj 19 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07146646The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04585750Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06282575Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT07780838A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06760819Distance-Based Exercise to Preserve Function and Prevent Disability
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07059884Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT05285358Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Ap rekriteFaz 1/2
Laj 18 a 99 · Tout sèks · Mizajou Jul 13, 2026 · NCT05000294Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT06101277Integrated Cancer Repository for Cancer Research
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Ap rekrite
Laj 18 a 99 · Tout sèks · Mizajou Feb 20, 2026 · NCT04907643Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.